European Commission to fund new flu research projects

Published: 18-Oct-2006

The European Commission is to give Euro 28.3m to 17 new research projects on avian and pandemic flu, half of which will concern human health. This funding is in addition to the €21m already provided by the Commission in this area.


The European Commission is to give Euro 28.3m to 17 new research projects on avian and pandemic flu, half of which will concern human health. This funding is in addition to the €21m already provided by the Commission in this area.

The aim of the human health-related projects is to improve understanding of the virus's mechanism of action. Projects will also include clinical research for vaccine development.

Human health projects include Euroflu, which will last three years and aims to study the molecular factors and mechanisms of the highly pathogenic avian flu virus. The Flupol project will study the molecular structure and function of the flu virus in order to understand how it adapts from avian to human hosts.

Fluvac will give pre-clinical evaluation to a whole inactivated H5N1 virus vaccine produced in cell culture, using new adjuvant IC31TM. The combination of the whole virus and IC31TM should provide broader immunity.

Another project involves an intranasal vaccine for the H5 strain of the virus, and will also be produced by cell culture. Meanwhile, Panfluvac aims to construct delivery systems for injectable and intranasal vaccines.

Countries that are not part of the Commission's framework programme for research will participate in nine of these projects - notably the US, Russia, China, Vietnam, Australia, Canada and Croatia. Small and medium-sized enterprises (SMEs) will also contribute to these projects, which are the result of a call for projects under the Commission's sixth framework research programme.

You may also like